Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study
RC48, used alone or in combination with PD-1 inhibitors, showed preliminary antitumor activity with manageable toxicity in patients with locally advanced or metastatic UTUC in this multicenter real-world cohort.
Authors
- Jianguo Wan (ORCID: https://orcid.org/0000-0003-1321-7930)
- Panpan Shang (ORCID: https://orcid.org/0009-0009-2251-3687)
- D. R. Li
- B. D. Zhang
- Can Li (ORCID: https://orcid.org/0000-0002-8873-0045)
- Xuan Li (ORCID: https://orcid.org/0000-0002-2988-946X)
- Su Zhang (ORCID: https://orcid.org/0000-0002-9322-5115)
- Shuaipeng He
- Zhongjin Yue
- Cheng Wang
- Gongjin Wu
- Junhai Ma
Institutions
- Lanzhou University Second Hospital (CN)
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1699538
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Lanzhou University